Tempus AI to Acquire Personalis in ~$1.9B Deal, Folding MRD Testing Into Its Precision Oncology Platform
Source: Businesswire — 2026-07-20
Summary
Tempus AI announced an all-stock acquisition of Personalis worth approximately $1.9 billion, with Merck — already a roughly 13% Personalis shareholder — backing the deal via a voting agreement. The acquisition integrates minimal residual disease (MRD) cancer-monitoring technology more tightly into Tempus's AI-enabled precision oncology platform, with Tempus citing the MRD testing market's roughly $20 billion size as the strategic target.
Key Takeaways
- The deal is structured as an all-stock transaction valued at roughly $1.9 billion, at a stated share price of $16.25.
- Merck, which already holds about 13% of Personalis, is backing the acquisition via a voting agreement — a notable existing-investor endorsement of the deal.
- Tempus frames the acquisition around capturing more of the ~$20 billion molecular residual disease (MRD) testing market by integrating MRD monitoring directly into its existing AI precision-oncology platform rather than partnering externally for it.